AstraZeneca to predict drug safety at Russian R&D center

AstraZeneca is investing in the development of computer systems to predict the safety and efficacy of new treatments at a planned Russian operation in St. Petersburg. The Predictive Science Centre, the latest in the London-based drug giant's series of projects in Russia, is expected to tap local talent to create the bioinformatics, data analytics and other tools needed for the new effort. The center appears to be a bet on computer systems to play a greater role in the company's R&D efforts. Item

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.